Skip to main content
SpringerLink
Log in

Clinical Toxicity of Interleukin-2

  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Interleukin-2 (IL2) is increasingly used to treat patients with cancers refractory to conventional treatment. Flu-like syndromes are extremely frequent but usually mild. A variety of skin implications (mostly erythema and mucositis) have been reported. Life-threatening skin reactions have also been described. Acute reactivation of psoriasis can also occur. Immediate hypersensitivity reactions have so far not been described, but IL-2 treatment has been shown to predispose to acute hypersensitivity reactions to iodine-containing contrast media.

Hypothyroidism is the major endocrine complication and antithyroid antibodies have been detected in approximately 50% of patients. Neurological and psychiatric disturbances with moderate severe mend status changes are common and sometimes treatment-limiting. The occurrence of peritumoural oedema in patients with brain metastases can also be a major practical problem. Musculoskeletal disorders are transient and resolve spontaneously.

The vascular leak syndrome is the most frequent and severe complication of IL-2 of which weight gain, generalised oedema, hypotension and impaired renal function are the main features. Even though a damaging effect on vascular endothelium cells by various cytokines released by activated lymphoid cells or mediated by non-lymphocyte-dependent factors has been proposed to be involved, the mechanism remains unclear. Other cardiovascular injuries, possibly life-threatening including myocarditis, angina pectoris and myocardial infarction, can occur during the first days of treatment. Supraventricular arrhythmias are the most common rhythmic disorder. Decreases in myocardial contractility and haemodynamic pattern similar to those of septic shock have been encountered in most cases.

Acute renal dysfunction is common but resolves with symptomatic management. Intrahepatic choleatasis with hyperbilirubinaemia is observed in most patients but permanent liver damage has not been described. Several cases of pancreatitis have been reported. Anaemia, thrombocytopenia, lymphocytopenia and eosinophilia are frequent and occur in most if not all patients. Some data suggest a high incidence of infectious complications, particularly in patients with surgically tunnelled catheters, but marked flu-like syndromes may be confounding. Finally, death directly related to IL-2 treatment has been noted in less than 1% of all patients. Investigations are under way to minimise IL-2 toxicity with varying dose regimens and combined treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abi-Aad AS, Figlin RA, Belldegrun A, de Kernion JB. Metastatic renal cell cancer interleukin-2 toxicity induced by contrast agent injection. Journal of Immunotherapy 10: 292–295, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ades EW, Bosse D, Orr S, Gillespie T. Immunologic effects of interleukin-2 adoptive immunotherapy in humans: acute in vitro anergy, in vivo antibody responses to tetanus. Pathobiology 58: 226–229, 1990

    Article  PubMed  CAS  Google Scholar 

  • Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, et al. The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 66: 2457–2464, 1990

    Article  PubMed  CAS  Google Scholar 

  • Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 13: 364–371, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ansher SS, Puri RK, Thompson WC, Habig WH. The effects of interleukin-2 and α-interferon administration on hepatic drug metabolism in mice. Cancer Research 52: 262–266, 1992

    PubMed  CAS  Google Scholar 

  • Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. New England Journal of Medicine 318: 1557–1563, 1988

    Article  PubMed  CAS  Google Scholar 

  • Aulitzky WE, Tilg H, Vogel W, Aulitzky W, Berger M, et al. Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. Annals of Hematology 62: 25–31, 1991

    Article  PubMed  CAS  Google Scholar 

  • Balmer CM. Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2. Drug Intelligence and Clinical Pharmacy 25: 490–498, 1991

    CAS  Google Scholar 

  • Baron NW, Davis LP, Flaherty LE, Muz J, Valdivieso M, et al. Scintigraphic findings in patients with shoulder pain caused by interleukin-2. American Journal of Roentgenology 154: 327–330, 1990

    PubMed  CAS  Google Scholar 

  • Bastuji-Garin S, Chosidow O, Lang P, Roujeau JC, Revuz J. Transient proteinuria during interleukin-2 therapy. European Journal of Cancer 26: 924–925, 1990

    Article  PubMed  CAS  Google Scholar 

  • Belldegrun A, Webb DE, Austin III HA, Steinberg SM, Linehan WM, et al. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. Journal of Urology 141: 499–503, 1989

    PubMed  CAS  Google Scholar 

  • Belldegrun A, Webb DE, Austin III HA, Steinberg SM, White DE, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Annals of Internal Medicine 106: 817–822, 1987

    PubMed  CAS  Google Scholar 

  • Bernard JT, Ameriso S, Kempf RA, Rosen P, Mitchell MS, et al. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 40: 154–155, 1990

    Article  PubMed  CAS  Google Scholar 

  • Berthaud P, Schlumberger M, Comoy E, Avril MF, Le Chevalier T, et al. Hypothyroidism and goitre during interleukin-2 therapy. Journal of Endocrinological Investigation 13: 689–690, 1990

    PubMed  CAS  Google Scholar 

  • Beuzeboc P, Escourolle H, Dorval T, Dieras V, Mastorakos G, et al. Hypothyroïdie après traitement par interleukin-2. Presse Médicale 18: 727, 1989

    CAS  Google Scholar 

  • Birchfield GR, Ward JH, Redman BG, Flaherty L, Samlowski WE. Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma. Western Journal of Medicine 152: 714–716, 1990

    PubMed  CAS  Google Scholar 

  • Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentuber D, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. Journal of Clinical Oncology 8: 161–169, 1990

    PubMed  CAS  Google Scholar 

  • Chabot GG, Flaherty LE, Valdivieso M, Baker LH. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemotherapy and Pharmacology 27: 157–160, 1990

    Article  PubMed  CAS  Google Scholar 

  • Chien CH, Hsieh K.H. lnterleukin-2 immunotherapy in children. Pediatrics 86: 937–943, 1990

    PubMed  CAS  Google Scholar 

  • Christiansen NP, Skubitz KM, Nath K, Ochoa A, Kennedy BJ. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. American Journal of Medicine 84: 1072–1075, 1988

    Article  PubMed  CAS  Google Scholar 

  • Cochat P, Floret D, BoufTet E, Francks CR, Favrot MC, et al. Renal effects of continuous infusion of recombinant interleukin-2 in children. Pediatric Nephrology 5: 33–37, 1991

    Article  PubMed  CAS  Google Scholar 

  • Conant EF, Fox KR, Miller WT. Pulmonary edema as a complication of interleukin-2 therapy. American Journal of Roentgenology 152: 749–752, 1989

    PubMed  CAS  Google Scholar 

  • Davis SD, Berkmen YM, Wang JCL. Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications. Radiology 177: 127–131, 1990

    PubMed  CAS  Google Scholar 

  • Denicoff KD, Durkin TM, Lotze MT, Quinlan PE, Davis CL, et al. The neuroendocrine effects of interleukin-2 treatment. Journal of Clinical Endocrinologv and Metabolism 69: 402–410, 1989

    Article  CAS  Google Scholar 

  • Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine 107: 293–300, 1987

    PubMed  CAS  Google Scholar 

  • Descotes J. Immunotoxicology of drugs and chemicals, 2nd ed., Elsevier Science Publishers, Amsterdam. 1988

    Google Scholar 

  • Diekman MJM, Vlasveld LT, Krediet RT, Rankin EM, Arisz L. Acute interstitial nephritis during continuous intravenous administration of low-dose interleukin-2. Nephron 60: 122–123, 1992

    Article  PubMed  CAS  Google Scholar 

  • Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma: a national biotherapy study group trial. Cancer 68: 1–8, 1991

    Article  PubMed  CAS  Google Scholar 

  • Emminger W, Emminger-Schmidmeier W, Peters C, Susani M, Hawlicyek R, et al. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rhGM-CSF) treatment of a patient in a continuous febrile state. Blut 61: 219–221, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, et al. Hematologic effects of immunotherapy with lymphokineactivated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654–1660, 1987

    PubMed  CAS  Google Scholar 

  • Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. Journal of Clinical Oncology 7: 1852–1862, 1989

    PubMed  CAS  Google Scholar 

  • Fishman JE, Aberle DR, Moldawer NP, Belldegrun A, Figlin RA. Atypical contrast reactions associated with systemic interleukin-2 therapy. American Journal of Roentgenology 156: 833–834, 1991

    PubMed  CAS  Google Scholar 

  • Flaherty LE, Schwert R, Redman BG. Development of Hodgkin’s disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma. Journal of the National Cancer Institute 82: 1360, 1990

    Article  PubMed  CAS  Google Scholar 

  • Fleischmann JD, Shingleton WB, Gallagher C, Ratnoff OD, Chahine A. Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. Journal of Laboratory and Clinical Medicine 117: 76–82, 1991

    PubMed  CAS  Google Scholar 

  • Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin-2 administration. Journal of the American Medical Association 258: 1624–1629, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gaynor ER, Vitek L, Sticklin L, Creekmore SP, Ferraro ME, et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine l09: 953–958, 1988

    Google Scholar 

  • Glauser FL, DeBlois G, Bechard D, Fowler AA, Merchant R, et al. Review: cardiopulmonary toxicity of adoptive immunotherapy. American Journal of the Medical Sciences 296: 406–412, 1988

    Article  PubMed  CAS  Google Scholar 

  • Guillaume JC, Escudier B, Espagne E, Roujeau JC, Prost C, et al. Dermatose bulleuse avec depots lineaires d’IgA le long de la membrane basale au cours d’un traitement par I’interferon gamma el l’interleukine-2. Annales de Dermatologie et de Venereologic 117: 899–902, 1990

    CAS  Google Scholar 

  • Hartmann L, Urba WJ, Steis RG, Smith II JW, Van der Molen L, et al. Hypothyroidism after interleukin-2. Journal of Clinical Oncology 7: 686, 1989

    PubMed  CAS  Google Scholar 

  • Heslan JMJ, Branellec AI, Lang P, Lagrue G. Recombinant interleukin-2-induced proteinuria: fact or artifact? Nephron 57: 373–374, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hisanaga S, Kawagoe H, Yamamoto Y, Kuroki N, Fujimoto S, et al. Nephrotic syndrome associated with recombinant interleukin-2. Nephron 54: 277–278, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hoffman M, Mittelman A, Dworkin B, Rosenthal W, Beneck D, et al. Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells. Journal of Cancer Research and Clinical Oncology 115: 175–178, 1989

    Article  PubMed  CAS  Google Scholar 

  • Jablons D, Bolton E, Mertins S, Rubin M, Pizzo P, et al. IL-2 based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. Journal of Immunology 144: 3630–3636, 1990

    CAS  Google Scholar 

  • Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. New England Journal of Medicine 322: 959–965, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kolitz JE, Mertelsmann RM. The immunotherapy of human cancer with interkeukin 2: present status and future directions. Cancer Investigation 9: 529–542, 1991

    Article  PubMed  CAS  Google Scholar 

  • Konrad MW, Hemstreet G, Hersh EM, Mansell PWA, Mertelsmann R, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Research 50: 2009–2017, 1990

    PubMed  CAS  Google Scholar 

  • Kradin RL, Kurnick JT, PrefTer FI, Dubinett SM, Dickersin GR, et al. Adoptive immunotherapy with IL-2 results in the loss of delayed type hypersensitivity to recall antigens. Clinical Immunology and Immunopathology 50: 184–195, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kragel AH, Travis WD, Feinberg L, Pittaluga S, Striker LM, et al. Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Human pathology 21: 493–502, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Kragel AH, Travis WD, Steis RG, Rosenberg SA, Roberts WC. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66: 1513–1516, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Krigel RL, Padavic-Shaller KA, Rudolph AR, Poiesz BJ, Comis RL. Exacerbation of epidemic Kaposi’s sarcoma with a combination of interleukin-2 and B-interferon: results of a Phase 2 Study. Journal of Biological Response Modifiers 65: 359–365, 1989

    Google Scholar 

  • Lavelle-Jones M, Al-Hadrani A, Spiers EM, Campbell FC, Cuschieri A. Reactivation of rheumatoid arthritis during continuous infusion of interleukin 2: evidence of lymphocytic control of rheumatoid disease. British Medical Journal 301: 97, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg ST. Interleukin 2 and psoriasis. Archives of Dermatology 124: 1811–1815, 1988

    Article  PubMed  CAS  Google Scholar 

  • Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. Journal of Clinical Oncology 7: 7–20, 1989

    PubMed  CAS  Google Scholar 

  • Lim SH, Callaghan T, Goldstone AH. Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. Acta Haematologica 85: 49–50, 1991

    Article  PubMed  CAS  Google Scholar 

  • MacDonald D, Gordon AA, Kajitani H, Enokihara H, Barrett AJ. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. British Journal of Haematology 76: 168–173, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mann H, Ward JH, Samlowski WE. Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology 176: 191–194, 1990

    PubMed  CAS  Google Scholar 

  • Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, et al. Severe hypovitaminosis C occurring as the result of immunotherapy with high-dose interleukin-2 and lymphokine-activated killer cells. Cancer Research 47: 4208–4212, 1987

    PubMed  CAS  Google Scholar 

  • Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. Journal of Clinical Oncology 7: 486–498, 1989

    PubMed  CAS  Google Scholar 

  • Mattijssen VJM, De Mulder PHM, Van Liessum PA, Corstens FHM, Franks CR, et al. Hypothyroidism and goitre in a patient during treatment with interleukin-2 therapy. Cancer 65: 2686–2688, 1990

    Article  PubMed  CAS  Google Scholar 

  • Michie HR, Eberlein TJ, Spriggs DR, Manogue KR, Cerami A, et al. Interleukin-2 initiates metabolic responses associated with critical illness in humans. Annals of Surgery 208: 493–501, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mier JW, Aronson FR, Numerof RP, Vachino G, Atkins MB. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathology and Immunopathology Research 7: 459–476, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Mier JW, Vachino G, Van Der Meer JWM, Numerof RP, Adams S, et al. Induction of circulating tumor necrosis factor (TNFa) as the mechanism for the febrile response to interleukin-2 in cancer patients. Journal of Clinical Immunology 8: 426–436, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon gamma. Annals of Internal Medicine 108: 36–41, 1988

    PubMed  CAS  Google Scholar 

  • Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ. Myocardial toxic effects during recombinant interleukin-2 therapy. Journal of the National Cancer Institute 81: 59–63, 1989

    Article  PubMed  CAS  Google Scholar 

  • Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, et al. Interleukin-2 administration causes reversible hemodynamic changes a n d left ventricular dysfunction similar to those seen in septic shock. Chest 94: 750–754, 1988

    Article  PubMed  CAS  Google Scholar 

  • Oldham RK, Brogley J, Braud E. Contrast medium ‘recalls’ interleukin-2 toxicity. Journal of Clinical Oncology 8: 942, 1990

    PubMed  CAS  Google Scholar 

  • Orcese C, Borri A, Besana C. Antibiotic prophylaxis to prevent catheter-related infections in recombinant interleukin-2 treated patients. Journal of Clinical Oncology 8: 1767–1769, 1990

    PubMed  CAS  Google Scholar 

  • Osanto S, Cluitmans FHM, Franks CR, Bosker HA, Cleton FJ. Myocardial injury after interleukin-2 therapy. Lancet 2: 48–49, 1988

    Article  PubMed  CAS  Google Scholar 

  • Paciucci PA, Mandeli J, Oleksowicz L, Ameglio F, Holland JF. Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. American Journal of Medicine 89: 308–312, 1990

    Article  PubMed  CAS  Google Scholar 

  • Pasini FL, Di Perri T, Van Der Plas K, Palmer P, Franks CR. Myocardial injury after interleukin-2 therapy. Lancet 1: 674, 1989

    Article  Google Scholar 

  • Perez R, Padavic K, Krigel R, Weiner L. Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon. Cancer 67: 2512–2517, 1991

    Article  PubMed  CAS  Google Scholar 

  • Pichert G, Jost LM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. British Journal of Cancer 63: 287–292, 1991

    Article  PubMed  CAS  Google Scholar 

  • Pichert G, Jost LM, Zobeli L, Odermatt B, Pedio G, et al. Thyroiditis after treatment with interleukin-2 and interferon a-2a. British Journal of Cancer 62: 100–104, 1990

    Article  PubMed  CAS  Google Scholar 

  • Punt CJA, Henzen-Logmans SC, Bolhuis RLH, Stoter G. Hyperbilirubinaemia in patients treated with recombinant human interleukin-2. British Journal of Cancer 61: 491, 1990

    Article  PubMed  CAS  Google Scholar 

  • Rahman R, Benrstein Z, Vaickus L, Penetrante R, Arbuck S, et al. Unusual gastrointestinal complications of interleukin-2 therapy. Journal of Immunotherapy 10: 221–225, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ramseur WL, Richard II Fm, Duggan DB. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2. Cancer 63: 2005–2007, 1989

    Article  PubMed  CAS  Google Scholar 

  • Richard V, Bernier M, Themelin L, Bron D, Sculier JP. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2. Annals of Oncology 2: 67–68, 1991

    Article  PubMed  CAS  Google Scholar 

  • Richards JM, Gilewski TA, Vogelzang NJ. Association of interleukin-2 therapy with staphylococcal bacteraemia. Cancer 67: 1570–1575, 1991

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine 316: 889–897, 1987

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals of Surgery 210: 474–485, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. Journal of Immunology 137: 1735–1742, 1986

    CAS  Google Scholar 

  • Samlowski WE, Ward JH, Craven CM, Freedman RA. Severe myocarditis following high-dose interleukin-2 administration. Archives of Pathology and Laboratory Medicine 113: 838–841, 1989

    PubMed  CAS  Google Scholar 

  • Saris SC, Patronas NJ, Rosenberg SA, Alexander JT, Frank J, et al. The effect of intravenous interleukin-2 on brain water content. Journal of Neurosurgery 71: 169–174, 1989

    Article  PubMed  CAS  Google Scholar 

  • Saxon RR, Klein JS, Bar MH, Blanc P, Gamsu G, et al. Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients. American Journal of Roentgenology 156: 281–285, 1991

    PubMed  CAS  Google Scholar 

  • Scalzo S, Gengaro A, Boccoli G, Masciulli R, Gianella G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. European Journal of Cancer 26: 1152–1156, 1990

    Article  PubMed  CAS  Google Scholar 

  • Schuchter LM, Hendricks CB, Holland KH, Shelton BK, Hutchins GM, et al. Eosinophilic myocarditis associated with high-dose interleukin-2 therapy. American Journal of Medicine 88: 439–440, 1990

    Article  PubMed  CAS  Google Scholar 

  • Schwartzentruber D, Lotze MT, Rosenberg SA. Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. Cancer 62: 2350–2353, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sculier JP, Bron D, Verboven N, Klastersky J. Multiple organ failure during interleukin-2 administration and LAK cells infusion. Intensive Care Medicine 14: 666–667, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sedgwick JB, Frick WE, Sondel PM, Hank JA, Borden E, et al. The appearance of hypodense eosinophils during interleukin-2 treatment. Journal of Allergy and Clinical Immunology 85: 557–566, 1990

    Article  PubMed  CAS  Google Scholar 

  • Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, et al. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. Journal of Clinical Oncology 8: 1839–1846, 1990

    PubMed  CAS  Google Scholar 

  • Shiloni E, Gross E, Shapiro M. Interleukin-2 therapy, central venous catheters, and nosocomial sepsis. Annals of Internal Medicine 112: 882–883, 1990

    PubMed  CAS  Google Scholar 

  • Siegel JP, Puri RK. Interleukin-2 toxicity. Journal of Clinical Oncology 9: 694–704, 1991

    PubMed  CAS  Google Scholar 

  • Silberstein DS, Schoof DD, Rodrick ML, Tai C, Spry CJF, et al. Activation of eosinophils in cancer patients treated with IL-2 and IL-2 generated lymphokine-activated killer cells. Journal of Immunology 142: 2162–2167, 1989

    CAS  Google Scholar 

  • Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, et al. Nosocomial sepsis associated with interleukin-2. Annals of Internal Medicine 112: 102–107, 1990

    PubMed  CAS  Google Scholar 

  • Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, et al. Repetitive weekly cycles of interleukin-2: II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. Journal of the National Cancer Institute 80: 1451–1461, 1988

    Article  PubMed  CAS  Google Scholar 

  • Staunton M, Scully MC, Le Boit PE, Aronson FR. Life-threatening bulbous skin eruptions during interleukin-2 therapy. Journal of the National Cancer Institute 83: 56–57, 1991

    Article  PubMed  CAS  Google Scholar 

  • Textor SC, Margolin K, Blayney D, Carlson J, Doroshow J. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. American Journal of Medicine 83: 1055–1061, 1987

    Article  PubMed  CAS  Google Scholar 

  • Thijs LG, Strack van Schijndel RJM, Wagstaff J. IL-2 induces clinical features of septic shock. Circulatory Shock 24: 201–207, 1988

    Google Scholar 

  • Thomas H, Vallis KA, Williams G, Waxman J. Ascites induced by interleukin-2 in the treatment of renal cancer. British Journal of Urology 65: 303–305, 1990

    Article  PubMed  CAS  Google Scholar 

  • Vaitkus PT, Fox KR, Doherty JU. Complete heart block due to interleukin-2 therapy. American Heart Journal 119: 978–980, 1990

    Article  PubMed  CAS  Google Scholar 

  • Van der Molen LA, Smith II JW, Longo DL, Steis RG, Kremers P, et al. Adrenal insufficiency and interleukin-2 therapy. Annals of Internal Medicine 111: 185, 1989

    Google Scholar 

  • Van Liessum PA, De Mulder PHM, Mattijssen EJM, Corstens FHM, Wagener DJTh. Hypothyroidism and goitre during interleukin-2 therapy without LAK cells. Lancet 1: 224, 1989

    Article  PubMed  Google Scholar 

  • Vecht CJ, Keohane C, Menon RS, Henzen-Logmans SC, Punt CJA, et al. Acute fatal leukoencephalopathy after interleukin-2 therapy. New England Journal of Medicine 323: 1146–1147, 1990

    PubMed  CAS  Google Scholar 

  • Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. Journal of Clinical Oncology 5: 496–503, 1987

    PubMed  CAS  Google Scholar 

  • Wallace DJ, Margolin K, Waller P. Fibromyalgia and interleukin-2 therapy for malignancy. Annals of Internal Medicine 108: 909, 1988

    PubMed  CAS  Google Scholar 

  • Webb DE, Austin III HA, Belldegrun A, Vaughan E, Linehan WM, et al. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clinical Nephrology 30: 141–145, 1988

    PubMed  CAS  Google Scholar 

  • Weinstein A, Bujak D, Mittelman A, Davidian M. Erythema nodosum in a patient with renal cell carcinoma treated with interleukin-2 and lymphokine-activated killer cells. Journal of the American Medical Association 258: 3120–3121, 1987

    Article  PubMed  CAS  Google Scholar 

  • Welbourn R, Goldman G, Kobzik L, Paterson I, Shepro D, et al. Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Annals of Surgery 214: 181–186, 1991

    Article  PubMed  CAS  Google Scholar 

  • West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, et al. Constant-infusion recombinant interleukin-2 in adoptive immuntherapy of advanced cancer. New England Journal of Medicine 316: 898–905, 1987

    Article  PubMed  CAS  Google Scholar 

  • Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. Journal of Clinical Oncology 6: 1440–1449, 1988

    PubMed  CAS  Google Scholar 

  • Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE. Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteis. Journal of Clinical Oncology 7: 1573–1578, 1989

    PubMed  CAS  Google Scholar 

  • Winkelhake JL, Gauny SS. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacological Reviews 42: 2–28, 1990

    Google Scholar 

  • Zaloom Y, Walsh LP, McCulloch P, Gallagher G. Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2. Immunology 72: 584–587, 1991

    PubMed  CAS  Google Scholar 

  • Zukiwski AA, David CL, Coan J, Wallace S, Gutterman JU, et al. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 65: 1521–1524, 1990

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire d’Immunotoxicologie Fondamentale et Clinique, INSERM U80, Faculté de Médecine Alexis Carrel, 69008, Lyon, France

    Thierry Vial & Jacques Descotes

Authors
  1. Thierry Vial
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Descotes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vial, T., Descotes, J. Clinical Toxicity of Interleukin-2. Drug-Safety 7, 417–433 (1992). https://doi.org/10.2165/00002018-199207060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199207060-00004

Keywords

Search

Navigation